Item 2.02 Results of Operations and Financial Condition. On January 8, 2026, Tango Therapeutics, Inc. (the “ Company”) disclosed that its cash, cash equivalents and marketable securities as of December 31, 2025 totaled $343 million (unaudited). The information in this Item 2.02 has not been audited and has been prepared by, and is the responsibility of, the Company’s management. The data could change as a result of further review and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Barbara Weber, M. D. as President and Chief Executive Officer On January 7, 2026, Barbara Weber, M. D. notified the board of directors (the “ Board”) of the Company of her retirement and resignation as President and Chief Executive Officer of the Company, in each case, effective as of January 8, 2026 (the “ Effective Date”). Dr. Weber and the Company entered into an amended and restated employment agreement (the “ Amended and Restated Employment Agreement”), effective as of the Effective Date, pursuant to which Dr. Weber has agreed to serve as the Company’s Executive Chair and to provide advisory services to assist in the orderly transition of her roles and responsibilities as President and Chief Executive Officer following the Effective Date through December 31, 2026. Pursuant to the terms of the Amended and Restated Employment Agreement, Dr. Weber will be entitled to: Annual base salary of $362,000; and Target cash bonus opportunity of 60% of Dr. Weber’s current annual base salary, pro-rated for any partial calendar year of service. Dr. Weber’s resignation as President and Chief Executive Officer and transition is not the result of any disagreement with respect to the Company’s operations, policies, or practices. Following the Effective Date, Dr. Weber will serve as chairperson of the Board. The foregoing description of the terms and conditions of the Amended and Restated Employment Agreement does not purport to be complete and is qualified in its entirety by the Amended and Restated Employment Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein. Appointment of Malte Peters, M. D. as President and Chief Executive Officer On January 8, 2026, Malte Peters, M. D., a member of the Board, was appointed as the Company’s President and Chief Executive Officer as of the Effective Date. Biographical information for Dr. Peters is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the U. S. Securities and Exchange Commission on April 21, 2025 and is incorporated herein by reference. In connection with his appointment as President and Chief Executive Officer, Dr. Peters entered into a compensation agreement with the Company (the “ Compensation Agreement”), effective January 8, 2026, and an employment agreement with the Company (the “ Employment Agreement”), effective upon the date on which Dr. Peters receives work authorization to work in the United States. The Compensation Agreement will expire upon the effective date of the Employment Agreement. Pursuant to the terms of the Compensation Agreement and the Employment Agreement Dr. Peters will be entitled to: Annual base salary of $720,000; Target cash bonus opportunity of 60% of Dr. Peter’s current annual base salary, pro-rated for any partial calendar year of service. The foregoing description of the terms and conditions of the Compensation Agreement and the Employment Agreement do not purport to be complete and are qualified in their entirety by the Compensation Agreement and the Employment Agreement, which are attached hereto as Exhibit 10.2 and 10.3, respectively and incorporated by reference herein. In connection with his appointment as President and Chief Executive Officer, Dr. Peters was also granted (i) an option to purchase 1,650,000 shares of the Company’s common stock under the Company’s 2021 Stock Option and Incentive Plan at an exercise price equal to the closing price of the Company’s common stock as reported on The Nasdaq Global Market on January 8, 2026, which will vest as to 25% of the shares underlying the option on the one year anniversary of the grant date, and the remainder vesting in 36 monthly thereafter (subject to Dr. Peter’s continued employment with the Company), and (ii) restricted stock units (“ RSUs”) to acquire 350,000 shares of the Company’s common stock, which shares will vest in three equal annual installments in accordance with Company’s equity incentive policies, in each case, subject to Dr. Peters’ continued employment with the Company. There are no understandings or arrangements between Dr. Peters and any other person pursuant to which he was appointed as the Company’s President and Chief Executive Officer. Except as described above, Dr. Peters does not have any material interest in any transaction or proposed transaction in which the Company is or is to be a party. Dr. Peters does not have a family relationship with any other director or executive officer of the Company. Consistent with the Company’s standard non-employeedirector compensation policy, Dr. Peters will not be eligible to receive compensation for his role on the Board since he is an executive officer.

Item 7.01 Regulation FD Disclosures. On January 8, 2026, the Company issued a press release announcing the leadership changes described above and updated its corporate presentation to be used from time to time with investors, analysts, and other third parties. Copies of the press release and the updated presentation are being furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form8-K. The information in Item 2.02 and 7.01 of this Current Report on Form8-Kand Exhibit 99.1 as well as Exhibit 99.2 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in the filing, unless specifically stated so therein.

Item 9.01. Financial Statements and Exhibits.